Related Experiment Video
Updated: Feb 14, 2026
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
22.3K
ATP Synthase, a Target for Dementia and Aging?
James W Larrick1,2, Jasmine W Larrick1, Andrew R Mendelsohn1,2
11 Panorama Research Institute , Sunnyvale, California.
Rejuvenation Research
|February 21, 2018
Summary
Aging increases the risk of fatal diseases like Alzheimer's dementia (AD). J147, a therapeutic molecule, targets mitochondrial ATP synthase, potentially offering a new avenue for AD treatment and lifespan extension.
Area of Science:
- Gerontology and Neurodegenerative Diseases
- Mitochondrial Biology
- Drug Discovery
Background:
- Advancing age is the primary risk factor for major life-threatening diseases, including Alzheimer's dementia (AD).
- Current AD therapies offer limited efficacy, primarily symptomatic relief without halting disease progression.
- J147 is a therapeutic molecule demonstrating efficacy in rescuing cognitive deficits in aged AD mouse models.
Purpose of the Study:
- To elucidate the mechanism of action for J147, a promising therapeutic candidate for Alzheimer's dementia.
- To investigate the molecular targets and pathways modulated by J147 in the context of aging and cognitive decline.
Main Methods:
- Mechanistic studies were performed to identify the molecular target of J147.
- Investigated the effects of J147 on mitochondrial alpha-F1-ATP synthase (ATP5A) activity.
- Assessed the downstream signaling pathways, including intracellular calcium modulation, AMP-activated protein kinase (AMPK), and mammalian target of rapamycin (mTOR) signaling.
Main Results:
- J147 was identified to target the mitochondrial alpha-F1-ATP synthase (ATP5A).
- Modest inhibition of ATP synthase by J147 modulates intracellular calcium levels.
- This modulation activates AMP-activated protein kinase (AMPK), leading to the inhibition of mammalian target of rapamycin (mTOR).
Conclusions:
- J147's mechanism involves the modulation of mitochondrial ATP synthase, impacting key cellular signaling pathways.
- The identified pathway (ATP synthase inhibition -> calcium modulation -> AMPK activation -> mTOR inhibition) is a known mechanism for lifespan extension.
- These findings suggest J147 as a potential therapeutic agent for Alzheimer's dementia and possibly for promoting longevity.
Related Concept Videos
01:18ATP Synthase: Structure
15.8K
ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
15.8K
01:48ATP Synthase: Mechanism
17.3K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
17.3K
01:30Dementia
580
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
580
01:31ATP Yield
79.2K
Cellular respiration produces 30 - 32 ATP per glucose molecule. Although most of the ATP results from oxidative phosphorylation and the electron transport chain (ETC), 4 ATP are gained beforehand (2 from glycolysis and 2 from the citric acid cycle).
The ETC is embedded in the inner mitochondrial membrane and is comprised of four main protein complexes and an ATP synthase. NADH and FADH2 pass electrons to these complexes, which pump protons into the intermembrane space. This distribution of...
The ETC is embedded in the inner mitochondrial membrane and is comprised of four main protein complexes and an ATP synthase. NADH and FADH2 pass electrons to these complexes, which pump protons into the intermembrane space. This distribution of...
79.2K
01:08Hydrolysis of ATP
82.0K
The bonds of adenosine triphosphate (ATP) can be broken through the addition of water, releasing one or two phosphate groups in an exergonic process called hydrolysis. This reaction liberates the energy in the bonds for use in the cell—for instance, to synthesize proteins from amino acids.
If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine...
If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine...
82.0K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
7
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
7